Overcoming maternal antibody-mediated immunosuppression

克服母源抗体介导的免疫抑制

基本信息

  • 批准号:
    8534701
  • 负责人:
  • 金额:
    $ 48.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-21 至 2017-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Maternally derived antibodies are crucial for protecting infants during their first months of life. This is best exemplified in infants with agammaglobulinemia, who thrive during the first year of life but succumb to repeated infections after the levels of circulating maternal antibodies wane. There is however, one downside to maternal antibodies; they suppress vaccine-induced activation of the infant immune system. Because of this, many necessary and life-saving vaccines such as measles are given at delayed times, up to a year after birth. This leaves a wide window of time during which the infant is vulnerable to infection but unable to develop the antibody response necessary for its own protection. Understanding how to activate the infant immune system in the presence of maternal antibodies is a critical area of research because it could lead to the development of more efficacious infant vaccines. We reasoned that maternal antibody-mediated suppression could in part be due to the form of the antigen used for vaccination. Our preliminary data show that immunization with soluble but not particulate antigens lead to significant activation of the infant immune system. Based upon this, our central hypothesis is that maternal antibody mediated immunosuppression of the new born immune system can be overcome and that robust long-term protective immunity can be generated by immunizing the new born with soluble rather than particulate antigens. We will test our central hypothesis by pursuing three specific aims. In Aim 1, we will fully characterize the infant immune responses induced by soluble antigens in the presence of maternal antibodies. In Aim 2, we will probe the extent of this protective immunity using H1N1, H3N2 and H5N1 influenza virus challenge models. Finally, in Aim 3, we will determine the extent to which maternal antibody mediated suppression can be overcome in non-human primate, rhesus macaque infants. The proposed work is significant because knowledge gained from these studies will enable us to develop vaccines that overcome maternal antibody suppression and can be used to successfully vaccinate infants.
描述(由申请人提供):母源性抗体对于在婴儿出生后的头几个月内保护婴儿至关重要。这在无丙种球蛋白血症的婴儿中得到了最好的例证,他们在生命的第一年茁壮成长,但在循环的母体抗体水平下降后死于反复感染。然而,母体抗体有一个缺点:它们抑制了疫苗诱导的婴儿免疫系统的激活。因此,许多必要且挽救生命的疫苗(例如麻疹)都是在出生后一年内延迟接种的。这就留下了一个很宽的时间窗口,在此期间,婴儿容易受到感染,但无法发展必要的抗体反应,以保护自己。了解如何在母体抗体存在的情况下激活婴儿免疫系统是一个关键的研究领域,因为它可能导致更有效的婴儿疫苗的开发。我们推断母体抗体介导的抑制可能部分是由于用于接种的抗原的形式。我们的初步数据表明,用可溶性而非颗粒性抗原免疫可导致婴儿的显著活化。 免疫系统基于此,我们的中心假设是,母体抗体介导的新生儿免疫系统的免疫抑制可以被克服,并且可以通过用可溶性抗原而不是颗粒抗原免疫新生儿来产生强大的长期保护性免疫。我们将通过追求三个具体目标来检验我们的中心假设。在目标1中,我们将充分表征在母体抗体存在下由可溶性抗原诱导的婴儿免疫应答。在目标2中,我们将使用H1N1、H3N2和H5N1流感病毒攻击模型来探测这种保护性免疫的程度。最后,在目标3中,我们将确定在非人灵长类动物恒河猴婴儿中可以克服母体抗体介导的抑制的程度。拟议的工作是重要的,因为从这些研究中获得的知识将使我们能够开发克服母体抗体抑制的疫苗,并可用于成功地为婴儿接种疫苗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOSHY JACOB其他文献

JOSHY JACOB的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOSHY JACOB', 18)}}的其他基金

Somatic hypermutation and rescue from self-reactivity in Pre-B lymphocytes
Pre-B 淋巴细胞的体细胞超突变和自身反应的拯救
  • 批准号:
    10153689
  • 财政年份:
    2020
  • 资助金额:
    $ 48.19万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    8704872
  • 财政年份:
    2012
  • 资助金额:
    $ 48.19万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    8899425
  • 财政年份:
    2012
  • 资助金额:
    $ 48.19万
  • 项目类别:
Negative regulation of Plasma cells by CD28 and B7 molecules
CD28 和 B7 分子对浆细胞的负调控
  • 批准号:
    8513589
  • 财政年份:
    2012
  • 资助金额:
    $ 48.19万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    9114473
  • 财政年份:
    2012
  • 资助金额:
    $ 48.19万
  • 项目类别:
Overcoming maternal antibody-mediated immunosuppression
克服母源抗体介导的免疫抑制
  • 批准号:
    8299339
  • 财政年份:
    2012
  • 资助金额:
    $ 48.19万
  • 项目类别:
B CELL MEMORY AND ORIGINAL ANTIGENIC SIN
B 细胞记忆和原罪抗原
  • 批准号:
    8357483
  • 财政年份:
    2011
  • 资助金额:
    $ 48.19万
  • 项目类别:
B CELL MEMORY
B细胞记忆
  • 批准号:
    8172441
  • 财政年份:
    2010
  • 资助金额:
    $ 48.19万
  • 项目类别:
B CELL MEMORY
B细胞记忆
  • 批准号:
    7958268
  • 财政年份:
    2009
  • 资助金额:
    $ 48.19万
  • 项目类别:
T CELL MEMORY
T细胞记忆
  • 批准号:
    7958181
  • 财政年份:
    2009
  • 资助金额:
    $ 48.19万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 48.19万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了